The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.
A breakthrough in bioprinting of living tissues could soon lead to 3D-printing of blood vessels and human organs, ushering in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback